{
"endpoint": "pubmed-search",
"count": 1,
"truncated": true,
"took_ms": 2850,
"items": [
{
"recordType": "paper",
"pmid": "41931049",
"title": "GLP-1 Receptor Agonists.",
"abstract": "Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor agonists and GLP-1 and glucose-dependent insulinotropic peptide agonists have several mechanisms of action, including reduction of gastric emptying, inhibition of glucagon secretion, beneficial changes in the intestinal microbiome, and direct effects on hypothalamic nuclei to enhance satiety (which promotes weight loss). Beyond the impressive effects of GLP-1 receptor agonists on blood glucose levels and body weight, large-scale randomized, controlled trials have shown that GLP-1 receptor agonists reduce cardiovascular risk and slow progression to renal failure in persons at high risk and those with type 2 diabetes. Adverse side effects from GLP-1 receptor agonists are mostly gastrointestinal but may also include loss of muscle and bone mass. Questions remain about long-term adherence, weight regain after discontinuation of treatment, and the functional implications of the loss of muscle and bone mass. Recent and ongoing targeted studies suggest the possibility of additional uses for GLP-1 receptor agonists.",
"authors": [
"Clifford J Rosen",
"Julie R Ingelfinger"
],
"authorCount": 2,
"firstAuthor": "Clifford J Rosen",
"journal": "The New England journal of medicine",
"journalAbbrev": "N Engl J Med",
"issn": "1533-4406",
"year": "2026",
"pubDate": "2026-04-02",
"volume": "394",
"issue": "13",
"pages": "1313-1324",
"pubTypes": [
"Journal Article",
"Review"
],
"meshTerms": [
"Humans",
"Cardiovascular Diseases",
"Diabetes Mellitus, Type 2",
"Glucagon-Like Peptide 1",
"Glucagon-Like Peptide-1 Receptor Agonists",
"Hypoglycemic Agents",
"Incretins",
"Obesity",
"Renal Insufficiency",
"Anti-Obesity Agents",
"Disease Progression",
"Gastric Emptying",
"Glucagon",
"Gastrointestinal Microbiome",
"Satiety Response",
"Randomized Controlled Trials as Topic",
"Medication Adherence"
],
"url": "https://pubmed.ncbi.nlm.nih.gov/41931049/",
"scrapedAt": "2026-11-11T16:06:22.336Z"
}
]
}
curl --location --request GET 'https://zylalabs.com/api/14840/pubmed+search+api/38492/search+pubmed+articles?query=GLP-1 obesity trial&sort=relevance&includeMesh=true&limit=2' --header 'Authorization: Bearer YOUR_API_KEY'
Después de registrarte, a cada desarrollador se le asigna una clave de acceso a la API personal, una combinación única de letras y dígitos proporcionada para acceder a nuestro endpoint de la API. Para autenticarte con el Búsqueda en PubMed API simplemente incluye tu token de portador en el encabezado de Autorización.
| Encabezado | Descripción |
|---|---|
Autorización
|
Requerido
Debería ser Bearer access_key. Consulta "Tu Clave de Acceso a la API" arriba cuando estés suscrito.
|
Sin compromiso a largo plazo. Mejora, reduce o cancela en cualquier momento.
(Ahorra 2 meses pagando anualmente 🎉)
Busca en PubMed y obtén artículos con PMID, resumen, autores, revista, año y términos MeSH
Cada respuesta es un JSON con un conteo un campo took_ms y un arreglo de items de registros planos listos para almacenar o consultar
No Las solicitudes se manejan del lado del servidor solo envías tu clave de API y los parámetros descritos en este endpoint
Cada llamada lee la fuente en vivo, por lo que los registros reflejan el estado de la fuente aguas arriba en el momento de la solicitud
Recibes un estado de error explícito en lugar de un resultado vacío por lo que un fallo nunca se confunde con la ausencia de datos
Sí cada endpoint limita el número de registros por solicitud el máximo se indica en el parámetro de límite